Heron Therapeutics licenses Long Grove products for US sale; pays undisclosed milestones and royalties

HERON THERAPEUTICS, INC. /DE/

Sept 23, 2026 Development and License Agreement with Long Grove Pharmaceuticals, LLC and Capstone Development Services Company, LLC.
Heron gets exclusive (as to licensed patents), sublicensable US rights to import, distribute, sell and market certain products.
Heron also gets a non-exclusive worldwide license to manufacture those products for sale in the Territory.
Heron owes regulatory milestone payments, sales-based milestones, royalties and expense reimbursement; no dollar amounts were disclosed.
Initial 10-year term from first commercial sale, automatic 2-year renewals; agreement to be filed with the Q3 2026 Form 10-Q.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.